Ankaferd Blood Stopper® (ABS) stimulates the formation of an encapsulated protein network containing fibrinogen, total protein, albumin and globin very quickly (< 1 second), and erythrocytes and platelets aggregate on this network. Ankaferd Blood Stopper acts on the primary and secondary hemostatic system without disturbing the coagulation factors, thanks to the protein network it stimulates the formation of blood cells and especially erythrocytes.

ABS is an easy-to-use, ideal topical hemostatic agent that is effective not only in venous bleeding but also in high-pressure arterial bleeding.

Figure 1. The basic mechanism of action of Ankaferd Blood Stopper (ABS) is the formation of an encapsulated protein network that provides focal points for erythrocyte aggregation. ABS-related formation of the unique protein network in vital erythroid aggregation covers the entire physiological hemostatic process. Red blood cell (RBC) elements (such as spectrin and ankrin surface receptors and the internal ferrochelatase enzyme), related transcription factors (such as GATA-1), and RBC-related proteins (such as urotensin II) are the main targets of abs. These proteins and the necessary ATP bioenergy are included in the Ankaferd protein library.

Figure 2. Plasma – microscopic image of Ankaferd Blood Stopper (ABS)-protein network formation in less than 1 second in serum and whole blood. ([A] before application and [B] immediately after Ankaferd application)

Reference

[1] Haznedaroglu BZ, Beyazit Y, Walker LS, Haznedaroglu IC. Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat. Critical Reviews in Oncology/Hematology 83 (2012) 21-34.